With the recent introduction of a number of highly effective disease-modifying treatments (DMTs) and the resulting almost complete prevention of acute relapses in many patients with multiple sclerosis (MS), the interest of MS clinicians has gradually shifted from relapse prevention to counteraction of disease progression and the treatment of residual symptoms. Targeting the cannabinoid system with nabiximols is an approved and effective strategy for the treatment of spasticity secondary to MS. Recently, the concept of spasticity plus syndrome (SPS) was introduced to account for the evidence that spasticity often appears in MS patients in clusters with other symptoms (such as pain, bladder dysfunction, sleep, and mood disorders), where cannabinoids can also be effective due to their broader action on many immune and neuronal functions. Interestingly, outside these symptomatic benefits, extensive pre-clinical and clinical research indicated how the modulation of the cannabinoid system results in significant anti-inflammatory and neuroprotective effects, all potentially relevant for MS disease control. This evidence makes nabiximols a potential disease modifying symptomatic treatment (DMST), a concept introduced in an attempt to overcome the often artificial distinction between DMTs and symptomatic therapies (STs).

Disease-modifying symptomatic treatment (DMST) potential of cannabinoids in patients with multiple sclerosis / Bruno, Antonio; Annovazzi, Pietro; Clerico, Marinella; Cocco, Eleonora; Conte, Antonella; Marfia, Girolama Alessandra; Salvetti, Marco; Torri Clerici, Valentina; Cleric, Valentina Torri; Totaro, Rocco; Dolcetti, Ettore; Centonze, Diego. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - (2024). [10.2174/011570159x329058240820070701]

Disease-modifying symptomatic treatment (DMST) potential of cannabinoids in patients with multiple sclerosis

Conte, Antonella;Salvetti, Marco;
2024

Abstract

With the recent introduction of a number of highly effective disease-modifying treatments (DMTs) and the resulting almost complete prevention of acute relapses in many patients with multiple sclerosis (MS), the interest of MS clinicians has gradually shifted from relapse prevention to counteraction of disease progression and the treatment of residual symptoms. Targeting the cannabinoid system with nabiximols is an approved and effective strategy for the treatment of spasticity secondary to MS. Recently, the concept of spasticity plus syndrome (SPS) was introduced to account for the evidence that spasticity often appears in MS patients in clusters with other symptoms (such as pain, bladder dysfunction, sleep, and mood disorders), where cannabinoids can also be effective due to their broader action on many immune and neuronal functions. Interestingly, outside these symptomatic benefits, extensive pre-clinical and clinical research indicated how the modulation of the cannabinoid system results in significant anti-inflammatory and neuroprotective effects, all potentially relevant for MS disease control. This evidence makes nabiximols a potential disease modifying symptomatic treatment (DMST), a concept introduced in an attempt to overcome the often artificial distinction between DMTs and symptomatic therapies (STs).
2024
cannabinoid; spasticity plus syndrome; multiple sclerosis; disease modifying therapies; neuroprotective effects; symptomatic therapies
01 Pubblicazione su rivista::01a Articolo in rivista
Disease-modifying symptomatic treatment (DMST) potential of cannabinoids in patients with multiple sclerosis / Bruno, Antonio; Annovazzi, Pietro; Clerico, Marinella; Cocco, Eleonora; Conte, Antonella; Marfia, Girolama Alessandra; Salvetti, Marco; Torri Clerici, Valentina; Cleric, Valentina Torri; Totaro, Rocco; Dolcetti, Ettore; Centonze, Diego. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - (2024). [10.2174/011570159x329058240820070701]
File allegati a questo prodotto
File Dimensione Formato  
Bruno_Disease-modifying_2024.pdf

solo gestori archivio

Note: Online ahead of print
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 574.08 kB
Formato Adobe PDF
574.08 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1729792
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact